Sanctuary Advisors LLC Sells 63 Shares of Insulet Co. (NASDAQ:PODD)

Sanctuary Advisors LLC reduced its position in Insulet Co. (NASDAQ:PODD) by 1.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,051 shares of the medical instruments supplier’s stock after selling 63 shares during the quarter. Sanctuary Advisors LLC’s holdings in Insulet were worth $943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in PODD. Blue Trust Inc. boosted its holdings in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in shares of Insulet in the second quarter worth $32,000. Venturi Wealth Management LLC boosted its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the period. UMB Bank n.a. grew its position in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its stake in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the period.

Insulet Stock Performance

NASDAQ:PODD opened at $266.57 on Monday. The company has a market capitalization of $18.70 billion, a price-to-earnings ratio of 45.65, a PEG ratio of 4.12 and a beta of 1.21. The business has a 50 day moving average of $254.48 and a 200 day moving average of $223.25. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77.

Insiders Place Their Bets

In related news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on PODD. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Wells Fargo & Company boosted their price objective on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. BTIG Research increased their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Barclays boosted their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $269.40.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.